VANCOUVER, Canada I November 12, 2013 I biOasis Technologies Inc. (TSX VENTURE:BTI)(BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, reported that new research conducted under its BT2111 (Herceptin®) program shows that BT2111-a conjugate of the metastatic cancer drug, Herceptin-not only crosses the blood-brain barrier, but also penetrates the blood-tumor barrier up to 10 times better than Herceptin alone.
BT2111 was developed by biOasis’s drug delivery platform, Transcend, which offers the creation of a new class of drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of metastatic cancer, as well as other brain diseases, like neurodegeneration and metabolic disease.
“Through image analysis and quantitative autoradiography in this animal study, we’ve now demonstrated that BT2111 distributed evenly in healthy sections of the brain, surrounded the metastatic brain cancer, and was present at significantly greater levels within the tumors compared to equal to or lower dose equivalence of Herceptin alone,” said Rob Hutchison, CEO of biOasis Technologies. “This observation corroborates the therapeutic responses seen in our prior animal models.”
“Treating cancer is extremely challenging as it is, but with brain tumors we have the additional hurdles of the blood-brain and blood-tumor barriers,” continued Hutchison. “Unfortunately, metastatic forms of brain cancer are even more problematic. MedlinePlus has reported that for many people with metastatic brain tumors the cancer is not curable. It will eventually spread to other areas of the body, with death often occurring within two years. This grim statistic has been a major compelling factor for us initiating the BT2111 program.”
“Understanding the mechanisms of actions of BT2111 is pivotal in the development of new therapeutic options for the treatment of HER2-positive metastatic brain cancer and other forms of metastatic brain cancers,” added Hutchison. “We are continuing our BT2111 program at a number of locations.”
In the treatment of brain tumors, drug delivery is complicated by the presence of the blood- brain barrier (BBB). The variability of the BBB and heterogeneity in permeability of the blood- tumour barrier (BTB) depends on tumor type, size, location, and prior treatments. There is complexity in the tumor microvessel populations (the brain-tumour barrier) that feed the growing metastatic cancer cells in the brain. The BTB remains a significant impediment to the use of standard chemotherapeutic delivery and efficacy in brain metastases of breast cancer. Recent research with anti-angiogenic treatment demonstrated that glioblastomas can continue to grow and even increase tissue invasion without the need for a second wave of angiogenesis. These findings indicate that primary brain tumors proliferate behind an intact BBB and that this barricade has to be crossed by any drug aimed to affect tumor growth.
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.
SOURCE: biOasis Technologies
Post Views: 171
VANCOUVER, Canada I November 12, 2013 I biOasis Technologies Inc. (TSX VENTURE:BTI)(BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, reported that new research conducted under its BT2111 (Herceptin®) program shows that BT2111-a conjugate of the metastatic cancer drug, Herceptin-not only crosses the blood-brain barrier, but also penetrates the blood-tumor barrier up to 10 times better than Herceptin alone.
BT2111 was developed by biOasis’s drug delivery platform, Transcend, which offers the creation of a new class of drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of metastatic cancer, as well as other brain diseases, like neurodegeneration and metabolic disease.
“Through image analysis and quantitative autoradiography in this animal study, we’ve now demonstrated that BT2111 distributed evenly in healthy sections of the brain, surrounded the metastatic brain cancer, and was present at significantly greater levels within the tumors compared to equal to or lower dose equivalence of Herceptin alone,” said Rob Hutchison, CEO of biOasis Technologies. “This observation corroborates the therapeutic responses seen in our prior animal models.”
“Treating cancer is extremely challenging as it is, but with brain tumors we have the additional hurdles of the blood-brain and blood-tumor barriers,” continued Hutchison. “Unfortunately, metastatic forms of brain cancer are even more problematic. MedlinePlus has reported that for many people with metastatic brain tumors the cancer is not curable. It will eventually spread to other areas of the body, with death often occurring within two years. This grim statistic has been a major compelling factor for us initiating the BT2111 program.”
“Understanding the mechanisms of actions of BT2111 is pivotal in the development of new therapeutic options for the treatment of HER2-positive metastatic brain cancer and other forms of metastatic brain cancers,” added Hutchison. “We are continuing our BT2111 program at a number of locations.”
In the treatment of brain tumors, drug delivery is complicated by the presence of the blood- brain barrier (BBB). The variability of the BBB and heterogeneity in permeability of the blood- tumour barrier (BTB) depends on tumor type, size, location, and prior treatments. There is complexity in the tumor microvessel populations (the brain-tumour barrier) that feed the growing metastatic cancer cells in the brain. The BTB remains a significant impediment to the use of standard chemotherapeutic delivery and efficacy in brain metastases of breast cancer. Recent research with anti-angiogenic treatment demonstrated that glioblastomas can continue to grow and even increase tissue invasion without the need for a second wave of angiogenesis. These findings indicate that primary brain tumors proliferate behind an intact BBB and that this barricade has to be crossed by any drug aimed to affect tumor growth.
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.
SOURCE: biOasis Technologies
Post Views: 171
